Pfizer, Inc. (NYSE:PFE) stock is moving slightly higher on Tuesday. The company on Monday reported top-line results of ABRYSVO, a novel vaccine, for respiratory syncytial virus (RSV) in immunocompromised adults.

What To Know: The results indicated that a single dose of ABRYSVO generates strong neutralizing responses against RSV-A and RSV-B in immunocompromised adults aged 18 and older. In addition, the vaccine was well-tolerated with a safety profile consistent with other studies of the vaccine.

The results come from Pfizer's substudy B of the Phase 3 MONeT trial which contained 203 immunocompromised adults.

"Immunocompromised adults, such as patients with cancer or autoimmune disorders, have a substantially increased risk of experiencing severe complications from RSV, yet there are currently no vaccines approved for those aged 18 to 59 in the U.S.," said Annaliesa Anderson, senior vice president and chief scientific officer, vaccine research and development, Pfizer.

"We are encouraged by the positive top-line data from this study, which provide important evidence that ABRYSVO has the potential to address a significant unmet need in this vulnerable population."

PFE Price Action: At the time of writing, Pfizer stock is trading 1.32% higher at $28.83, according to data from Benzinga Pro.

Image: Photo via Shutterstock